Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Clinical Advisory Board

Ian J. Constable, MD
Chair

Dr. Constable is Founder and Professor of Ophthalmology at the Lions Eye Institute, University of Western Australia, and is an expert in gene therapy approaches to retinal disease.


Mark S. Blumenkranz, MD

Dr. Blumenkranz is Professor and Chairman at the Byers Eye Institute at Stanford. He is a renowned expert in retinal disease and has founded several Silicon Valley startup companies.


Steven D. Schwartz, MD

Dr. Schwartz is Professor of Ophthalmology and Chief of Retina Division at the UCLA Jules Stein Eye Institute. He is a renowned expert in retinal diseases and early-stage clinical research.


Judy Gordon, DVM

Dr. Gordon is a Clinical Regulatory Consultant with extensive experience in Ophthalmology products.


Steven Butler, PhD

Dr. Butler is a Consulting Biostatistician. As an Associate Director at Genentech, he served as the lead biostatistician and development sub-team leader for Lucentis.

Avalanche Biotechnologies, Inc. Reports Second Quarter 2014 Financial Results

September 11, 2014

MENLO PARK, Calif., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today reported financial results and operational highlights for the quarter ended June 30, 2014.

Read More

Read All Avalanche News